MARKET

PRAX

PRAX

Praxis Precision Medicines, Inc.
NASDAQ
258.92
+2.45
+0.96%
After Hours: 258.92 0 0.00% 19:30 10/22 EDT
OPEN
253.05
PREV CLOSE
256.47
HIGH
263.82
LOW
253.05
VOLUME
355.67K
TURNOVER
--
52 WEEK HIGH
392.70
52 WEEK LOW
154.45
MARKET CAP
7.23B
P/E (TTM)
-20.0260
1D
5D
1M
3M
1Y
5Y
1D
Piper Sandler Remains a Buy on Praxis Precision Medicines (PRAX)
TipRanks · 1d ago
3 ‘Strong Buy’ High-Risk Stocks with Double-Gain Potential
TipRanks · 1d ago
Weekly Report: what happened at PRAX last week (1012-1016)?
Weekly Report · 4d ago
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Madrigal Pharmaceuticals (MDGL)
TipRanks · 5d ago
UBS Initiates Coverage of Praxis Precision Medicines with Buy
NASDAQ · 6d ago
JP Morgan Initiates Coverage of Praxis Precision Medicines at Overweight
NASDAQ · 6d ago
Praxis Precision Med Initiated at Overweight by JP Morgan
Dow Jones · 6d ago
Praxis Precision Med Price Target Announced at $700.00/Share by JP Morgan
Dow Jones · 6d ago
More
About PRAX
Praxis Precision Medicines, Inc. is an integrated, central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company's product candidates include Ulixacaltamide, Vormatrigine, Relutrigine, PRAX-080, Elsunersen, and others.

Webull offers Praxis Precision Medicines Inc stock information, including NASDAQ: PRAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRAX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRAX stock methods without spending real money on the virtual paper trading platform.